Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor

Kai,Keita; Masuda,Masanori; Ide,Takao; Takase,Yukari; Miyoshi,Atsushi; Kitahara,Kenji; Miyazaki,Kohji; Noshiro,Hirokazu; Tokunaga,Osamu

doi:10.3892/mco.2013.121

Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor

Authors:
- Keita Kai
- Masanori Masuda
- Takao Ide
- Yukari Takase
- Atsushi Miyoshi
- Kenji Kitahara
- Kohji Miyazaki
- Hirokazu Noshiro
- Osamu Tokunaga
View Affiliations

Affiliations: Department of Pathology and Microbiology, Saga University, Faculty of Medicine, Saga City, Safa 849-8501, Japan, Department of Surgery, Saga University, Faculty of Medicine, Saga City, Safa 849-8501, Japan
Published online on: May 16, 2013 https://doi.org/10.3892/mco.2013.121
Pages: 633-638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The surgical strategy for gallbladder cancer (GBC) depends on the extent of the disease. Thus, the identification of useful prognostic markers exerting strong prognostic impact for each T stage would be beneficial in the development of rational therapeutic strategies. The purpose of this study was to identify useful prognostic markers of GBC for each T stage. CD8+ tumor‑infiltrating lymphocytes (TIL), Ki-67 labeling index (LI), p53 nuclear expression and mitotic count (MC) were investigated as candidate prognostic markers. In total, 86 patients with invasive GBC were included. Of the prognostic markers examined, only MC showed a correlation with reduced survival (P=0.0383) in the univariate analysis of overall T stage. In the univariate analysis of T2 stage (n=31), only high p53 expression correlated with survival showing a positive correlation (P=0.0154). In the univariate analysis of T3 stage (n=40), the only factor showing a significant correlation with survival was MC (P=0.0113). Multivariate analysis, including N and M as factors, identified only MC as an independent prognostic factor in T3 stage GBC (P=0.0419). In conclusion, this study demonstrated the strong prognostic impact of MC in GBC, particularly in patients with T3 tumor.

View Figures

View References

1.	Sobin L, Gospodarowicz M and Wittekind C: TNM Classification of Malignant Tumors. 7th edition. John Wiley & Sons, Inc; Hoboken, NJ: 2009
2.	Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H and Ohtani H: CD8⁺T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58:3491–3494. 1998.PubMed/NCBI
3.	Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macrì E, Lanza G, Boiocchi M and Dolcetti R: Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol. 159:297–304. 2001. View Article : Google Scholar
4.	Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H and Nishimura M: CD4⁺T cells in cancer stroma, not CD8⁺T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 94:1003–1009. 2003.
5.	Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H and Barten M: Prognostic role of CD8⁺tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 35:808–816. 2004.
6.	Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S and Katoh H: CD8⁺tumor-infiltrating lymphocytes together with CD4⁺tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 28:e26–e31. 2004.
7.	Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR and Lugli A: Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer. 112:495–502. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T and Nijman HW: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 58:449–459. 2009. View Article : Google Scholar : PubMed/NCBI
9.	de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H and Nijman HW: Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol. 114:105–110. 2009.PubMed/NCBI
10.	Shah W, Yan X, Jing L, Zhou Y, Chen H and Wang Y: A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+) FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol. 8:59–66. 2011.PubMed/NCBI
11.	Seethala RR, Hunt JL, Baloch ZW, Livolsi VA and Leon Barnes E: Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am J Surg Pathol. 31:1683–1694. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Leuverink EM, Brennan BA, Crook ML, Doherty DA, Hammond IG, Ruba S and Stewart CJ: Prognostic value of mitotic counts and Ki-67 immunoreactivity in adult-type granulosa cell tumour of the ovary. J Clin Pathol. 61:914–919. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Wrba F, Reiner A, Markis-Ritzinger E, Holzner JH, Reiner G and Spona J: Prognostic significance of immunohistochemical parameters in breast carcinomas. Pathol Res Pract. 183:277–283. 1988. View Article : Google Scholar : PubMed/NCBI
14.	Bruner JM: Neuropathology of malignant gliomas. Semin Oncol. 21:126–138. 1994.PubMed/NCBI
15.	Greenblatt MS, Grollman AP and Harris CC: Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res. 56:2130–2136. 1996.PubMed/NCBI
16.	Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E and Coggi G: p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol. 24:1175–1179. 1993. View Article : Google Scholar : PubMed/NCBI
17.	Fontanini G, Vignati S, Lucchi M, Mussi A, Calcinai A, Boldrini L, Chiné S, Silvestri V, Angeletti CA, Basolo F and Bevilacqua G: Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer. 75:1295–1301. 1997. View Article : Google Scholar : PubMed/NCBI
18.	Assimakopoulos D, Kolettas E, Zagorianakou N, Evangelou A, Skevas A and Agnantis NJ: Prognostic significance of p53 in the cancer of the larynx. Anticancer Res. 20:3555–3564. 2000.PubMed/NCBI
19.	Pancione M, Forte N, Fucci A, Sabatino L, Febbraro A, Di Blasi A, Daniele B, Parente D and Colantuoni V: Prognostic role of beta-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Hum Pathol. 41:867–876. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Sumithran E, Susil BJ and Looi LM: The prognostic significance of grading in borderline mucinous tumors of the ovary. Hum Pathol. 19:15–18. 1988. View Article : Google Scholar : PubMed/NCBI
21.	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. CW Elston and IO Ellis. Histopathology. 1991.19:403–410, Histopathology 41: 151–153, 2002.
22.	Van Eeden S, Quaedvlieg PF, Taal BG, Offerhaus GJ, Lamers CB and Van Velthuysen ML: Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 33:1126–1132. 2002.PubMed/NCBI
23.	Kadota K, Suzuki K, Colovos C, Sima CS, Rusch VW, Travis WD and Adusumilli PS: A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 25:260–271. 2012.PubMed/NCBI
24.	Storr SJ, Safuan S, Mitra A, Elliott F, Walker C, Vasko MJ, Ho B, Cook M, Mohammed RA, Patel PM, Ellis IO, Newton-Bishop JA and Martin SG: Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol. 25:493–504. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Pilgrim C, Usatoff V and Evans PM: A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour. Eur J Surg Oncol. 35:903–907. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Mekeel KL and Hemming AW: Surgical management of gall-bladder carcinoma: a review. J Gastrointest Surg. 11:1188–1193. 2007. View Article : Google Scholar
27.	Wakai T, Shirai Y, Yokoyama N, Nagakura S, Watanabe H and Hatakeyama K: Early gallbladder carcinoma does not warrant radical resection. Br J Surg. 88:675–678. 2001. View Article : Google Scholar : PubMed/NCBI
28.	Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S and Katoh H: Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer. 89:1736–1742. 2003. View Article : Google Scholar : PubMed/NCBI
29.	Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S and Saitoh Y: p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology. 43:521–526. 1996.PubMed/NCBI
30.	Hidalgo Grau LA, Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogués JM and Sala JS: Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB; Oxford: 6. pp. 174–180. 2004
31.	Kim YW, Huh SH, Park YK, Yoon TY, Lee SM and Hong SH: Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas. Oncol Rep. 8:1127–1132. 2001.PubMed/NCBI
32.	Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D’Angelica M, Blumgart LH and Singh B: Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol. 24:1152–1160. 2006. View Article : Google Scholar
33.	Kim WB, Han HJ, Lee HJ, Park SS, Song TJ, Kim HK, et al: Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer. Ann Surg Oncol. 16:23–34. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Lee CS and Pirdas A: p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater. Pathology. 27:117–120. 1995. View Article : Google Scholar : PubMed/NCBI
35.	Chang HJ, Yoo BC, Kim SW, Lee BL and Kim WH: Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res. 13:326–335. 2007. View Article : Google Scholar : PubMed/NCBI
36.	Roa EI, Lantadilla HS, Ibacache SG and de Aretxabala UX: p53 and p27 gene expression in subserosal gallbladder carcinoma. Rev Med Chil. 137:1017–1022. 2009.(In Spanish).
37.	Wistuba II, Gazdar AF, Roa I and Albores-Saavedra J: p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 27:360–365. 1996. View Article : Google Scholar : PubMed/NCBI
38.	Kamel D, Pääkkö P, Nuorva K, Vähäkangas K and Soini Y: p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol. 170:67–72. 1993. View Article : Google Scholar : PubMed/NCBI
39.	Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K and Saito T: Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas. Pathol Int. 47:525–530. 1997. View Article : Google Scholar : PubMed/NCBI
40.	Oohashi Y, Watanabe H, Ajioka Y and Hatakeyama K: p53 immunostaining distinguishes malignant from benign lesions of the gall-bladder. Pathol Int. 45:58–65. 1995. View Article : Google Scholar : PubMed/NCBI
41.	Shrestha ML, Miyake H, Kikutsuji T and Tashiro S: Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J Med Invest. 45:95–102. 1998.PubMed/NCBI
42.	Kohya N and Miyazaki K: Hepatectomy of segment 4a and 5 combined with extra-hepatic bile duct resection for T2 and T3 gallbladder carcinoma. J Surg Oncol. 97:498–502. 2008. View Article : Google Scholar : PubMed/NCBI